Buy now: sentiment/catalysts are strongly positive while price is sitting near key support after a selloff, creating a favorable risk/reward for an impatient entry.
Options positioning is notably bullish (very low put/call on both OI and volume), suggesting traders are leaning to upside continuation/bounce.
Near-term setup: technically still in a downtrend, but oversold conditions + support proximity increase the odds of a rebound attempt.
Street view has turned sharply more constructive with multiple Buy ratings and large price-target step-ups following FDA/regulatory clarity.
Options activity vs normal: today’s volume vs 30D avg = 33.44% (not a volume spike), but today vs OI avg = 98.88% suggests positioning is meaningful relative to typical open interest.
Volatility: IV30 87.85 vs HV 115.94 (implied below realized); IV percentile 60.8 / IV rank 21.38 = elevated but not extreme for the name.
Technical Summary
Sell
5
Buy
7
Positive Catalysts
FDA Fast Track designation (2026-02-02) for sonelokimab in moderate-to-severe palmoplantar pustulosis: supports faster development and keeps positive regulatory momentum.
Recent regulatory clarity (per analysts): Type B FDA meeting outcome (referenced by multiple firms) implying a cleaner path toward registration/BLA and reduced “extra trial” risk.
Strongly improving Wall Street sentiment with multiple Buy ratings and materially higher price targets in early Jan 2026.
Neutral/Negative Catalysts
are reclaimed.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 0 (still pre-commercial).
Net income improved YoY to -69.7M (data indicates improvement vs prior year).
EPS improved YoY to -1.10 (loss narrowing per provided YoY change).
Overall: fundamentals are typical for a development-stage biotech; the trade is primarily driven by regulatory/clinical milestones rather than current earnings power.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: meaningfully more bullish following FDA/regulatory update.
2026-01-08 Clear Street: Buy, PT raised $12 → $45 (major step-up after Type B meeting).
2026-01-09 BTIG: Upgraded to Buy from Neutral, PT $24 (cites overhang removal and potential approval pathway).
2026-01-09 H.C. Wainwright: Buy, PT $26 → $32.
Wall Street pros: clearer regulatory path, reduced development risk, potentially faster timeline.
Wall Street cons: development-stage uncertainty remains; valuation is largely expectation-based until commercialization.
Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 24.1 USD with a low forecast of 5 USD and a high forecast of 45 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 24.1 USD with a low forecast of 5 USD and a high forecast of 45 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
2 Hold
1 Sell
Moderate Buy
Current: 14.770
Low
5
Averages
24.1
High
45
Current: 14.770
Low
5
Averages
24.1
High
45
BTIG
Neutral -> Buy
upgrade
$24
AI Analysis
2026-01-09
Reason
BTIG
Price Target
$24
AI Analysis
2026-01-09
upgrade
Neutral -> Buy
Reason
BTIG upgraded MoonLake Immunotherapeutics to Buy from Neutral with a $24 price target. The firm cites yesterday's regulatory update for the upgrade. A Type B meeting with the FDA confirmed that MoonLakecould establish substantial evidence of effectiveness of SLK in hidradenitis suppurativa without conducting additional clinical studies, the analyst tells investors in a research note. BTIG says this "positive update clears a significant overhang" for MoonLake's clinical development and could position SLK to receive FDA approval.
H.C. Wainwright
Buy
maintain
$26 -> $32
2026-01-09
Reason
H.C. Wainwright
Price Target
$26 -> $32
2026-01-09
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on MoonLake Immunotherapeutics to $32 from $26 and keeps a Buy rating on the shares. The company's FDA Type B meeting outcome delineates a path to registration, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MLTX
